Status:
COMPLETED
Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers
Lead Sponsor:
Alios Biopharma Inc.
Conditions:
Respiratory Syncytial Virus Infections
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will assess the safety, tolerability, and pharmacokinetics (PK) of orally administered ALS-008176 in healthy volunteers.
Eligibility Criteria
Inclusion
- Male or female subjects, 18-55 years of age, in good health with screening laboratory values within limits specified by the protocol
- Body mass index 18-30 kg/m2
- Female subjects must be of non-childbearing potential; male subjects must be surgically sterile or practicing birth control
Exclusion
- Clinically significant or uncontrolled medical illness
- Use, or anticipated use during conduct of the study, of concomitant medications
Key Trial Info
Start Date :
May 31 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2013
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT01906164
Start Date
May 31 2013
End Date
November 30 2013
Last Update
October 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site
Rennes, France